FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379512112> ?p ?o ?g. }

• W4379512112 endingPage "209" @default.
• W4379512112 startingPage "208.2" @default.
• W4379512112 abstract "Background A significant unmet medical need remains in the treatment of relapsed and/or refractory B cell-driven autoimmune diseases, including lupus nephritis (LN). The presence of autoantibodies is a hallmark of such diseases and implicates dysregulated B cell function in their pathogenesis. The central role of B cells in these diseases is also supported by the presence of B cells in diseased tissues and the efficacious responses reported with biologic therapies that target B cells. KYV-101 is an autologous CD19 CAR-T cell therapy that depletes pathogenic B cells. Importantly, the CD19 CAR utilized in KYV-101 was previously tested in B-cell lymphoma patients and demonstrated efficacy with an improved safety profile [1]. Since CD19 CAR-T cells target and lyse B cells in both circulation and tissues, a more complete depletion of autoreactive B cells is expected with KYV-101, resulting in better disease control and clinical remission than the current immunotherapies. Objectives To demonstrate the CAR-mediated and CD19-dependent activity of KYV-101 against autologous, patient-derived primary B cells. Methods Autologous CD4 + and CD8 + T cells were enriched from healthy donors (HD), systemic lupus erythematosus (SLE), LN or other autoimmune patients. KYV-101 CAR T cells were transduced with a lentiviral vector encoding a fully human single-chain variable fragment (scFV) CD19-targeting domain, a CD8α hinge and transmembrane domain, a CD28 cytoplasmic costimulatory domain, and a CD3ζ cytoplasmic domain. The CAR-mediated and CD19-dependent activity of KYV-101 was monitored in vitro in a set of cytotoxicity, cytokine release and proliferation studies, in response to either CD19 + target cell lines or autologous, patient-derived primary CD19 + B cells. Results Following a 24-hour incubation, KYV-101 generated from HDs or autoimmune patients induced greater and dose-dependent cytotoxicity of both the human CD19 + NALM6 cell line and autologous, patient-derived primary B cells than their respective untransduced control T cells. Moreover, an effector cell dose-dependent increase in the production of cytokines such as IFNγ was also observed following co-culture. In contrast, no differences in cytotoxicity nor cytokine production were observed when CD19 - target cells (K562 or U937 cells) were co-cultured with KYV-101 or untransduced control T cells. In addition, following a 96-hour incubation, KYV-101 generated from HDs or autoimmune patients proliferated when co-cultured with the NALM6 cells and autologous, patient derived primary B cells, whereas substantially lower levels of proliferation were observed in the untransduced control T cells co-cultured with NALM6 or autologous, patient-derived primary B cells or in KYV-101 and untransduced control T cells co-cultured with the CD19 - cell lines K562 and U937. Conclusion KYV-101 generated from autoimmune disease patient lymphocytes demonstrates CAR-mediated and CD19-dependent activity against autologous, patient-derived primary B cells and thus represents a novel therapeutic option for the depletion of pathogenic B cells in autoimmune patients. Reference [1]Brudno JN, et al., Nat Med , 2020, 26(2):270-280 Figure 1. KYV-101-mediated A) cytotoxicity, B) cytokine release and C) proliferation when co-cultured with autologous, patient-derived CD19 + human B cells. Acknowledgements: NIL. Disclosure of Interests Soo Park Employee of: Kyverna Therapeutics, Ames Register Employee of: Kyverna Therapeutics, Ho-Young Lee Employee of: Kyverna Therapeutics, Gloria Lutzny-Geier Grant/research support from: Kyverna Therapeutics, Michael Aigner Grant/research support from: Kyverna Therapeutics, Mackensen Andreas Grant/research support from: Kyverna Therapeutics, Georg Schett Grant/research support from: Kyverna Therapeutics, Dominique Borie Employee of: Kyverna Therapeutics, James Chung Employee of: Kyverna Therapeutics, Charles Kaplan Employee of: Kyverna Therapeutics." @default.
• W4379512112 created "2023-06-07" @default.
• W4379512112 creator A5005627673 @default.
• W4379512112 creator A5040043698 @default.
• W4379512112 creator A5043813813 @default.
• W4379512112 creator A5050161186 @default.
• W4379512112 creator A5053550462 @default.
• W4379512112 creator A5060345055 @default.
• W4379512112 creator A5075261558 @default.
• W4379512112 creator A5078101542 @default.
• W4379512112 creator A5079989008 @default.
• W4379512112 creator A5085724062 @default.
• W4379512112 date "2023-05-30" @default.
• W4379512112 modified "2023-10-16" @default.
• W4379512112 title "POS0007 KYV-101, A FULLY HUMAN CD19 CAR T CELL GENERATED FROM AUTOIMMUNE PATIENT LYMPHOCYTES, DEMONSTRATES CAR-MEDIATED AND CD19-DEPENDENT ACTIVITY AGAINST AUTOLOGOUS B CELLS" @default.
• W4379512112 doi "https://doi.org/10.1136/annrheumdis-2023-eular.6228" @default.
• W4379512112 hasPublicationYear "2023" @default.
• W4379512112 type Work @default.
• W4379512112 citedByCount "0" @default.
• W4379512112 crossrefType "journal-article" @default.
• W4379512112 hasAuthorship W4379512112A5005627673 @default.
• W4379512112 hasAuthorship W4379512112A5040043698 @default.
• W4379512112 hasAuthorship W4379512112A5043813813 @default.
• W4379512112 hasAuthorship W4379512112A5050161186 @default.
• W4379512112 hasAuthorship W4379512112A5053550462 @default.
• W4379512112 hasAuthorship W4379512112A5060345055 @default.
• W4379512112 hasAuthorship W4379512112A5075261558 @default.
• W4379512112 hasAuthorship W4379512112A5078101542 @default.
• W4379512112 hasAuthorship W4379512112A5079989008 @default.
• W4379512112 hasAuthorship W4379512112A5085724062 @default.
• W4379512112 hasBestOaLocation W43795121121 @default.
• W4379512112 hasConcept C126322002 @default.
• W4379512112 hasConcept C147483822 @default.
• W4379512112 hasConcept C159654299 @default.
• W4379512112 hasConcept C167672396 @default.
• W4379512112 hasConcept C203014093 @default.
• W4379512112 hasConcept C2778453870 @default.
• W4379512112 hasConcept C2778957590 @default.
• W4379512112 hasConcept C2779134260 @default.
• W4379512112 hasConcept C2779912601 @default.
• W4379512112 hasConcept C71924100 @default.
• W4379512112 hasConceptScore W4379512112C126322002 @default.
• W4379512112 hasConceptScore W4379512112C147483822 @default.
• W4379512112 hasConceptScore W4379512112C159654299 @default.
• W4379512112 hasConceptScore W4379512112C167672396 @default.
• W4379512112 hasConceptScore W4379512112C203014093 @default.
• W4379512112 hasConceptScore W4379512112C2778453870 @default.
• W4379512112 hasConceptScore W4379512112C2778957590 @default.
• W4379512112 hasConceptScore W4379512112C2779134260 @default.
• W4379512112 hasConceptScore W4379512112C2779912601 @default.
• W4379512112 hasConceptScore W4379512112C71924100 @default.
• W4379512112 hasIssue "Suppl 1" @default.
• W4379512112 hasLocation W43795121121 @default.
• W4379512112 hasOpenAccess W4379512112 @default.
• W4379512112 hasPrimaryLocation W43795121121 @default.
• W4379512112 hasRelatedWork W1536852484 @default.
• W4379512112 hasRelatedWork W162997378 @default.
• W4379512112 hasRelatedWork W1981184132 @default.
• W4379512112 hasRelatedWork W1989929570 @default.
• W4379512112 hasRelatedWork W1998321994 @default.
• W4379512112 hasRelatedWork W2022391508 @default.
• W4379512112 hasRelatedWork W2068674819 @default.
• W4379512112 hasRelatedWork W2349088313 @default.
• W4379512112 hasRelatedWork W2365203071 @default.
• W4379512112 hasRelatedWork W2375849257 @default.
• W4379512112 hasVolume "82" @default.
• W4379512112 isParatext "false" @default.
• W4379512112 isRetracted "false" @default.
• W4379512112 workType "article" @default.